NVCR

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About NovoCure Ltd

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
CEO
Asaf Danziger
Employees
1023
Headquarters

Forum
No 4 Grenville Street, Saint Helier JE2 4UF
Phone: 441534756700
www.novocure.com

News

Results of Novocure''s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Apr 24, 2024 14:48pm

Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society o…


Source:Finanz Nachrichten
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Apr 24, 2024 14:45pm

Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4. METIS was a randomized phase 3 clinical trial of stereotactic radiosurgery with or without Tumor Treating Fields Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
NovoCure shares get price target boost on positive outlook
Apr 10, 2024 11:28am

https://www.investing.com/news/company-news/novocure-shares-get-price-target-boost-on-positive-outlook-93CH-3372898


Source:Investing.com
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
Apr 05, 2024 11:00am

Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego. The presentations, describing preclinical investigations, include new insights on how TTFields therapy can potentially enhance the immune system’s ability to combat Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
NVCR, SBNY and VITL are among after hour movers
Apr 01, 2024 21:08pm

No summary available.


Source:Seeking Alpha
Novocure to Report First Quarter 2024 Financial Results
Apr 01, 2024 11:00am

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three months ended March 31, 2024, at 8:00 a.m. EDT on Thursday, May 2, 2024. To access the conference call by phone, Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Why NovoCure Stock Soared 18.3% This Week
Mar 30, 2024 10:34am

Novocure announced encouraging results in a phase 3 trial for its TTFields therapy.


Source:The Motley Fool
Why Novocure Stock Is Jumping Today
Mar 28, 2024 15:50pm

Novocure had good news mixed with some not-so-good news.


Source:The Motley Fool
NovoCure: Sell The METIS-Inspired Rally
Mar 28, 2024 02:55am

NovoCure''s METIS trial results raise doubts about TTFields'' efficacy in NSCLC treatment, leading to a sell recommendation for NVCR stock. Read more here.


Source:Seeking Alpha
Novocure’s stock surges after positive results in brain-cancer trial
Mar 27, 2024 18:26pm

Novocure Ltd.’s stock soared 15% Wednesday after the company announced positive results from a late-stage trial of a medtech device to treat patients with lung cancer that has spread to their brains.


Source:MarketWatch